固酶抑制剂:一种治疗方法对诱导的神经毒性
Sonia Bhatt1, Ajay Pal Singh1, Sokindra Kumar2
1School of Pharmacy, Lingaya's Vidyapeeth, Nachauli, Faridabad, India.
Drug metabolism and bioanalysis letters
|April 29, 2025
概括
暴露会损害大脑,但PDE4和PDE1抑制剂罗利普拉姆和文波西丁显示出有前途. 这些药物改善了大脑健康,并减少了暴露于的老鼠的神经毒性.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 毒性是全球重要的健康问题.
- 长期暴露于会导致发育和成人大脑的认知障碍.
- 酸酸盐诱导神经毒性,影响大脑发育和功能.
研究的目的:
- 为了研究罗利普拉姆 (一种PDE4抑制剂) 和文波 (一种PDE1抑制剂) 对Sprague-Dawley大鼠中酸诱导的神经毒性的神经保护作用.
- 评估这些抑制剂对海马体生化标志物和蛋白质表达的影响.
主要方法:
- 测量了血液中的度,以评估积累.
- 大脑重量被评估为神经毒性的指标.
- 进行了生物化学测定,以检测马隆迪化物 (MDA),谷氨 (GSH),催化酶 (CAT) 和超氧化物失调酶 (SOD).
- 在海马组织中分析了CREB (cAMP反应元素结合蛋白) 和P-CREB的蛋白质表达.
主要成果:
- 罗利普拉姆和文波西丁显著改善了大脑体重,抵消了引起的减肥.
- 这些抑制剂的使用逆转了抗氧化剂活性下降,并减少了炎症.
- 罗利普拉姆和文波西丁都显著增加了大鼠海马中的CREB和P-CREB表达.
结论:
- 抑制固酶4 (PDE4) 和固酶1 (PDE1) 为引起的神经毒性提供了潜在的治疗策略.
- 罗利普拉姆和文波西丁显示出对毒性的神经保护性质.
- 向PDE4和PDE1可能是减轻引起的大脑损伤的新药疗法.
相关概念视频
01:26Anticholinesterase Agents: Poisoning and Treatment
733
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
733
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
551
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
551
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
473
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
473
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
85
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
85